At Genet, we offer the “Oncomine Tumor Mutation Load Assay,” a cutting-edge service designed to identify cancer driver variants and evaluate tumor mutational burden (TMB), a promising immuno-oncology biomarker, utilizing next-generation sequencing technology.
Immune checkpoint inhibitors have revolutionized cancer treatment across various types, yet not all patients experience a positive response to immunotherapies. This highlights the critical role of relevant biomarkers in guiding the selection of suitable treatment options for each patient.
Given the intricate nature of immune response and tumor biology, there is a growing need for additional biomarkers to assess their relationship with the effectiveness of immuno-oncology (I-O) therapies. Tumor mutational burden (TMB) is one such emerging biomarker with potential applications across multiple disease types, which can contribute to further advancements in immunotherapy research.
Oncomine Tumor Mutation Load Assay is a highly reliable, targeted next-generation sequencing (NGS) assay, specifically designed for tumor profiling through the identification of cancer driver variants and precise TMB quantification using limited formalin-fixed, paraffin-embedded (FFPE) samples. Our integrated, streamlined analysis solution enables you to confidently detect cancer driver variants and evaluate tumor mutational burden in approximately 2.5 days for your research endeavors.
